Cargando…
ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses
Prime-boost regimens for COVID-19 vaccines elicit poor antibody responses against Omicron-based variants and employ frequent boosters to maintain antibody levels. We present a natural infection-mimicking technology that combines features of mRNA- and protein nanoparticle-based vaccines through encod...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810232/ https://www.ncbi.nlm.nih.gov/pubmed/36597535 http://dx.doi.org/10.1101/2022.12.26.521940 |
_version_ | 1784863268654809088 |
---|---|
author | Hoffmann, Magnus A. G. Yang, Zhi Huey-Tubman, Kathryn E. Cohen, Alexander A. Gnanapragasam, Priyanthi N. P. Nakatomi, Leesa M. Storm, Kaya N. Moon, Woohyun J. Lin, Paulo J.C. Bjorkman, Pamela J. |
author_facet | Hoffmann, Magnus A. G. Yang, Zhi Huey-Tubman, Kathryn E. Cohen, Alexander A. Gnanapragasam, Priyanthi N. P. Nakatomi, Leesa M. Storm, Kaya N. Moon, Woohyun J. Lin, Paulo J.C. Bjorkman, Pamela J. |
author_sort | Hoffmann, Magnus A. G. |
collection | PubMed |
description | Prime-boost regimens for COVID-19 vaccines elicit poor antibody responses against Omicron-based variants and employ frequent boosters to maintain antibody levels. We present a natural infection-mimicking technology that combines features of mRNA- and protein nanoparticle-based vaccines through encoding self-assembling enveloped virus-like particles (eVLPs). eVLP assembly is achieved by inserting an ESCRT- and ALIX-binding region (EABR) into the SARS-CoV-2 spike cytoplasmic tail, which recruits ESCRT proteins to induce eVLP budding from cells. Purified spike-EABR eVLPs presented densely-arrayed spikes and elicited potent antibody responses in mice. Two immunizations with mRNA-LNP encoding spike-EABR elicited potent CD8+ T-cell responses and superior neutralizing antibody responses against original and variant SARS-CoV-2 compared to conventional spike-encoding mRNA-LNP and purified spike-EABR eVLPs, improving neutralizing titers >10-fold against Omicron-based variants for three months post-boost. Thus, EABR technology enhances potency and breadth of vaccine-induced responses through antigen presentation on cell surfaces and eVLPs, enabling longer-lasting protection against SARS-CoV-2 and other viruses. |
format | Online Article Text |
id | pubmed-9810232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-98102322023-01-04 ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses Hoffmann, Magnus A. G. Yang, Zhi Huey-Tubman, Kathryn E. Cohen, Alexander A. Gnanapragasam, Priyanthi N. P. Nakatomi, Leesa M. Storm, Kaya N. Moon, Woohyun J. Lin, Paulo J.C. Bjorkman, Pamela J. bioRxiv Article Prime-boost regimens for COVID-19 vaccines elicit poor antibody responses against Omicron-based variants and employ frequent boosters to maintain antibody levels. We present a natural infection-mimicking technology that combines features of mRNA- and protein nanoparticle-based vaccines through encoding self-assembling enveloped virus-like particles (eVLPs). eVLP assembly is achieved by inserting an ESCRT- and ALIX-binding region (EABR) into the SARS-CoV-2 spike cytoplasmic tail, which recruits ESCRT proteins to induce eVLP budding from cells. Purified spike-EABR eVLPs presented densely-arrayed spikes and elicited potent antibody responses in mice. Two immunizations with mRNA-LNP encoding spike-EABR elicited potent CD8+ T-cell responses and superior neutralizing antibody responses against original and variant SARS-CoV-2 compared to conventional spike-encoding mRNA-LNP and purified spike-EABR eVLPs, improving neutralizing titers >10-fold against Omicron-based variants for three months post-boost. Thus, EABR technology enhances potency and breadth of vaccine-induced responses through antigen presentation on cell surfaces and eVLPs, enabling longer-lasting protection against SARS-CoV-2 and other viruses. Cold Spring Harbor Laboratory 2022-12-27 /pmc/articles/PMC9810232/ /pubmed/36597535 http://dx.doi.org/10.1101/2022.12.26.521940 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Hoffmann, Magnus A. G. Yang, Zhi Huey-Tubman, Kathryn E. Cohen, Alexander A. Gnanapragasam, Priyanthi N. P. Nakatomi, Leesa M. Storm, Kaya N. Moon, Woohyun J. Lin, Paulo J.C. Bjorkman, Pamela J. ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses |
title | ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses |
title_full | ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses |
title_fullStr | ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses |
title_full_unstemmed | ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses |
title_short | ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses |
title_sort | escrt recruitment to mrna-encoded sars-cov-2 spike induces virus-like particles and enhanced antibody responses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810232/ https://www.ncbi.nlm.nih.gov/pubmed/36597535 http://dx.doi.org/10.1101/2022.12.26.521940 |
work_keys_str_mv | AT hoffmannmagnusag escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses AT yangzhi escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses AT hueytubmankathryne escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses AT cohenalexandera escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses AT gnanapragasampriyanthinp escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses AT nakatomileesam escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses AT stormkayan escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses AT moonwoohyunj escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses AT linpaulojc escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses AT bjorkmanpamelaj escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses |